T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.
|Videos|January 9, 2018
Could Novel Hybrid Imaging Predict Breast Cancer Prognosis?
Author(s)Stephen Grobmyer, MD
This video highlights a study on optoacoustic imaging, a new type of imaging that could improve breast cancer diagnosis by differentiating between benign and malignant breast masses.
Advertisement
In this video, Stephen Grobmyer, MD, of the Cleveland Clinic in Ohio, discusses a study on optoacoustic imaging, a new type of imaging combining laser optics and ultrasound that could improve breast cancer diagnosis by differentiating between benign and malignant breast masses.
Grobmyer presented the study (
Advertisement
Related to this article
Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.
NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer, backed by DESTINY-Breast04 data.
Trastuzumab botidotin more than doubled median PFS vs trastuzumab emtansine in HER2-positive advanced breast cancer in the phase 3 KL166-III-06 trial.
Camizestrant/palbociclib did not significantly improve PFS vs anastrozole/palbociclib in first-line ER+/HER2– breast cancer in the phase 3 SERENA-4 trial.
Erica L. Mayer, MD, MPH, discussed the practical questions clinicians must answer as the SERENA-6 early-switch approach with camizestrant enters practice.
Erica L. Mayer, MD, MPH, explained why oncologists should switch to camizestrant at ESR1 mutation emergence rather than reserve oral SERDs for progression.
The panel discussed the risk-benefit profile of the Galleri multicancer early detection test, which was evaluated in the NHS-Galleri and PATHFINDER 2 studies.